Literature DB >> 27026485

The current management of cholangiocarcinoma: A comparison of current guidelines.

Yulong Cai1, Nansheng Cheng, Hui Ye, Fuyu Li, Peipei Song, Wei Tang.   

Abstract

Cholangiocarcinoma (CC) accounts for about 3% of all gastrointestinal tumors and is the second most common primary liver tumor. Quality guidelines on CC are needed to guide hepatobiliary surgeons. Here, current guidelines on CC were reviewed to provide useful information and suggestions to help institutes and organizations all around the world to draft better guidelines on CC. Literature databases were electronically searched to identify guidelines or consensus statements regarding CC published from 2002-2016. Nine guidelines were included in this review. Comparison of the current guidelines revealed several inconsistencies. Signs of conflicting views indicated a lack of high level evidence. More studies need to be conducted in areas of contention to help update the guidelines. Organizations and medical societies need to be encouraged to use standard evaluation measures, to restrict tumors to CC or iCC, pCC, or dCC specifically, to give recommendations in accordance with the equipment that is available for diagnosis and treatment in different counties, and to use an appropriate and consistent structure when establishing and drafting guidelines for CC.

Entities:  

Mesh:

Year:  2016        PMID: 27026485     DOI: 10.5582/bst.2016.01048

Source DB:  PubMed          Journal:  Biosci Trends        ISSN: 1881-7815            Impact factor:   2.400


  25 in total

Review 1.  Cholangiocarcinoma: Classification, Histopathology and Molecular Carcinogenesis.

Authors:  Gábor Lendvai; Tímea Szekerczés; Idikó Illyés; Réka Dóra; Endre Kontsek; Alíz Gógl; András Kiss; Klára Werling; Ilona Kovalszky; Zsuzsa Schaff; Katalin Borka
Journal:  Pathol Oncol Res       Date:  2018-11-17       Impact factor: 3.201

2.  Digital single-operator cholangioscopy: a useful tool for selective guidewire placements across complex biliary strictures.

Authors:  Arne Bokemeyer; Dina Gross; Markus Brückner; Tobias Nowacki; Dominik Bettenworth; Hartmut Schmidt; Hauke Heinzow; Iyad Kabar; Hansjoerg Ullerich; Frank Lenze
Journal:  Surg Endosc       Date:  2018-07-13       Impact factor: 4.584

Review 3.  [Surgical approach to benign bile duct alterations].

Authors:  A Alvanos; S Rademacher; A Hoffmeister; D Seehofer
Journal:  Chirurg       Date:  2020-01       Impact factor: 0.955

4.  Preliminary results in unresectable cholangiocarcinoma treated by CT percutaneous irreversible electroporation: feasibility, safety and efficacy.

Authors:  Maria Paola Belfiore; Alfonso Reginelli; Nicola Maggialetti; Mattia Carbone; Sabrina Giovine; Antonella Laporta; Fabrizio Urraro; Valerio Nardone; Roberta Grassi; Salvatore Cappabianca; Luca Brunese
Journal:  Med Oncol       Date:  2020-04-09       Impact factor: 3.064

5.  Construction of a competing endogenous RNA network related to the prognosis of cholangiocarcinoma and comprehensive analysis of the immunological correlation.

Authors:  Ning Wang; Yinghui Zhou; Zhifan Zuo; Ruoyu Wang; Jing Li; Tao Han; Bin Yang
Journal:  J Gastrointest Oncol       Date:  2021-10

6.  Prognostic Utility of Systemic Immune-Inflammation Index After Resection of Extrahepatic Cholangiocarcinoma: Results from the U.S. Extrahepatic Biliary Malignancy Consortium.

Authors:  Junya Toyoda; Kota Sahara; Shishir K Maithel; Daniel E Abbott; George A Poultsides; Christopher Wolfgang; Ryan C Fields; Jin He; Charles Scoggins; Kamran Idrees; Perry Shen; Itaru Endo; Timothy M Pawlik
Journal:  Ann Surg Oncol       Date:  2022-06-29       Impact factor: 4.339

7.  The expression and clinicopathological role of CDX2 in intrahepatic cholangiocarcinoma.

Authors:  Haowen Tang; Zhanbo Wang; Wenping Lv; Xuan Meng
Journal:  Intractable Rare Dis Res       Date:  2018-05

8.  Inflammation-based prognostic scores in patients with extrahepatic bile duct lesions treated by percutaneous transhepatic biliary stenting combined with 125I seeds intracavitary irradiation.

Authors:  X Hu; Q Pang; H Liu; Z Qian; H Jin; L Zhou; Y Wang; Z Man; Z Li; S Yang
Journal:  Clin Transl Oncol       Date:  2018-10-27       Impact factor: 3.405

9.  USP9X promotes apoptosis in cholangiocarcinoma by modulation expression of KIF1Bβ via deubiquitinating EGLN3.

Authors:  Weiqian Chen; Jingjing Song; Siyu Liu; Bufu Tang; Lin Shen; Jinyu Zhu; Shiji Fang; Fazong Wu; Liyun Zheng; Rongfang Qiu; Chunmiao Chen; Yang Gao; Jianfei Tu; Zhongwei Zhao; Jiansong Ji
Journal:  J Biomed Sci       Date:  2021-06-10       Impact factor: 8.410

Review 10.  Interventional Treatment for Cholangiocarcinoma.

Authors:  Hang Li; Li Chen; Guang-Yu Zhu; Xijuan Yao; Rui Dong; Jin-He Guo
Journal:  Front Oncol       Date:  2021-06-29       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.